Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IOVA | Iovance Biotherapeutics, Inc.

IndexRUT P/E- EPS (ttm)-2.25 Insider Own0.10% Shs Outstand247.78M Perf Week-6.55%
Market Cap1.08B Forward P/E- EPS next Y-1.43 Insider Trans- Shs Float232.91M Perf Month-21.95%
Income-418.80M PEG- EPS next Q-0.45 Inst Own91.41% Short Float / Ratio12.91% / 4.96 Perf Quarter-38.97%
Sales0.20M P/S5377.85 EPS this Y-11.40% Inst Trans-2.38% Short Interest30.07M Perf Half Y-14.35%
Book/sh2.58 P/B1.91 EPS next Y24.50% ROA-60.00% Target Price22.36 Perf Year-50.90%
Cash/sh1.15 P/C4.29 EPS next 5Y- ROE-78.30% 52W Range4.41 - 10.41 Perf YTD-22.93%
Dividend- P/FCF- EPS past 5Y-12.00% ROI- 52W High-52.69% Beta0.13
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low11.68% ATR0.47
Employees503 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)36.35 Volatility10.87% 7.15%
OptionableYes Debt/Eq0.00 EPS Q/Q24.90% Profit Margin- Rel Volume0.77 Prev Close5.03
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume6.06M Price4.93
Recom1.80 SMA20-14.78% SMA50-25.61% SMA200-28.61% Volume2,726,776 Change-2.18%
Date Action Analyst Rating Change Price Target Change
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Jun-10-21Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Sep-15-23 04:20PM
Sep-14-23 06:10PM
Sep-07-23 11:30AM
07:31AM Loading…
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Aug-08-23 05:50PM
Jul-31-23 06:10AM
Jul-25-23 04:01PM
04:01PM Loading…
Jul-24-23 04:01PM
Jul-21-23 05:34PM
Jul-13-23 04:01PM
Jul-11-23 04:30PM
Jul-10-23 09:46PM
Jun-24-23 03:19PM
Jun-20-23 07:01AM
Jun-16-23 08:39AM
Jun-15-23 07:01AM
07:01AM Loading…
Jun-09-23 07:01AM
Jun-08-23 11:30AM
May-30-23 04:18PM
May-29-23 10:08AM
May-26-23 05:30PM
May-24-23 12:03PM
May-16-23 09:25AM
May-11-23 01:40PM
May-10-23 12:16PM
May-09-23 04:01PM
May-02-23 04:01PM
May-01-23 04:00PM
Apr-24-23 07:01AM
Apr-20-23 09:45AM
Apr-06-23 07:22AM
Mar-30-23 11:30AM
Mar-27-23 03:56PM
Mar-24-23 04:01PM
Mar-21-23 05:10PM
Mar-04-23 08:13AM
Mar-02-23 09:17PM
Mar-01-23 12:33PM
Feb-28-23 04:01PM
Feb-27-23 09:31AM
Feb-21-23 04:01PM
Jan-24-23 12:15PM
Jan-23-23 06:37PM
Dec-16-22 09:54AM
Dec-11-22 07:23AM
Nov-30-22 07:00AM
Nov-21-22 12:11PM
Nov-18-22 01:06PM
Nov-12-22 08:34AM
Nov-10-22 12:33PM
Nov-07-22 08:01AM
Nov-04-22 12:31PM
Nov-03-22 04:01PM
Oct-27-22 07:19PM
Oct-24-22 04:01PM
Oct-11-22 11:49AM
Oct-10-22 07:30AM
Oct-05-22 09:45AM
Sep-12-22 07:00AM
Sep-06-22 04:01PM
Aug-26-22 01:13PM
Aug-25-22 01:05PM
Aug-05-22 12:13PM
Aug-04-22 04:01PM
Jul-27-22 07:00AM
Jul-22-22 05:15PM
Jun-22-22 10:48AM
Jun-17-22 05:15PM
Jun-13-22 04:01PM
Jun-12-22 09:00AM
Jun-08-22 04:01PM
Jun-06-22 08:34PM
Jun-05-22 09:06AM
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universite de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCPEAK MERRILL ADirectorSep 18Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
BILINSKY IGORChief Operating OfficerJul 14Option Exercise0.002,813028,608Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14Option Exercise0.0020,834081,701Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 14Option Exercise0.002,812030,930Apr 18 05:49 PM
Vogt Frederick GInterim CEO & General CounselApr 14Option Exercise0.0020,834069,718Apr 18 05:50 PM
BILINSKY IGORChief Operating OfficerApr 14Option Exercise0.002,812027,190Apr 18 05:48 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 17Option Exercise0.0011,248032,796Jan 19 04:52 PM
BILINSKY IGORChief Operating OfficerJan 17Option Exercise0.0011,248029,049Jan 19 04:52 PM
Vogt Frederick GInterim CEO & General CounselJan 17Option Exercise0.0083,325085,325Jan 19 04:51 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 03Option Exercise0.0019,690032,571Jan 05 08:57 PM
BILINSKY IGORChief Operating OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
Bellemin Jean-MarcChief Financial OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
MCPEAK MERRILL ADirectorDec 21Buy6.1510,00061,50070,150Dec 22 04:06 PM
Rothbaum Wayne P.DirectorDec 02Buy6.5010,000,00065,000,00018,067,333Dec 02 05:29 PM
MCPEAK MERRILL ADirectorNov 29Buy6.3110,00063,100238,633Nov 30 04:17 PM
MCPEAK MERRILL ADirectorNov 28Buy6.1810,00061,800228,633Nov 28 09:44 PM
Vogt Frederick GInterim CEO & General CounselNov 28Buy5.981,0005,9802,000Nov 28 09:46 PM
Dukes Iain D.DirectorNov 23Buy6.1010,00061,00022,000Nov 28 09:43 PM